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The actions of angiotensin peptides are diverse and locally acting tissue renin–angiotensin
systems (RAS) are present in almost all tissues of the body. An activated RAS strongly cor-
relates to metabolic disease (e.g., diabetes) and its complications and blockers of RAS have
been demonstrated to prevent diabetes in humans. Hyperglycemia, obesity, hypertension,
and cortisol are well-known risk factors of metabolic disease and all stimulate tissue RAS
whereas glucagon-like peptide-1, vitamin D, and aerobic exercise are inhibitors of tissue
RAS and to some extent can prevent metabolic disease. Furthermore, an activated tissue
RAS deteriorates the same risk factors creating a system with several positive feedback
pathways. The primary effector hormone of the RAS, angiotensin II, stimulates reactive
oxygen species, induces tissue damage, and can be associated to most diabetic compli-
cations. Based on these observations, we hypothesize that an activated tissue RAS is the
principle cause of metabolic syndrome and type 2 diabetes, and additionally is mediating
the majority of the metabolic complications. The involvement of positive feedback path-
ways may create a self-reinforcing state and explain why metabolic disease initiate and
progress. The hypothesis plausibly unifies the major predictors of metabolic disease and
places tissue RAS regulation in the center of metabolic control.
Keywords: renin–angiotensin system, diabetes, metabolic syndrome, obesity, GLP-1, cortisol, vitamin D,
osteoporosis
INTRODUCTION
The renin–angiotensin system (RAS) is classically considered to
play key roles in regulating blood pressure as well as water
and sodium balance. Liver secreted angiotensinogen (AGT) is
enzymatically cleaved to angiotensin (ANG) I by kidney-derived
renin. ANG I is, hereafter, cleaved by angiotensin converting
enzyme (ACE) to the effector hormone ANG II. This classi-
cal theory has, however, been fundamentally revised in recent
years. It is now evident that the components of RAS, in addi-
tion to the classical pathway, are produced and acting locally
in multiple tissues; a concept known as tissue RAS. The local
effects are diverse and depend on the specific tissues involved.
Additional components (angiotensin peptides, receptors, and
enzymes) of the system have been identified but ANG II is
still believed to exert the most important actions via the ANG
II receptor type 1 (AT1R). Although many details on tissue
RAS have been elucidated, the main function of the systems
still remains partly unknown. For reviews on tissue RAS see
Ref. (1–3).
It is well established that an activated RAS is a major
risk factor of both cardiovascular (4) and renal disease (5).
Inhibitors of RAS [ACE inhibitors, ANG II receptor block-
ers (ARB), and renin inhibitors] are therefore widely used in
the clinic. The RAS is also closely associated to the meta-
bolic syndrome (6) and recently, inhibitors of RAS have shown
to prevent the onset of type 2 diabetes (T2D) in high risk
populations (7, 8).
These latter findings suggest an important role of RAS in meta-
bolic disease. However, compared to hormones such as glucagon-
like peptide-1 (GLP-1) or cortisol, the RAS may seem only a weak
regulator of metabolism. We will challenge this perception and
argue that the tissue RAS can be considered as the most central
player in metabolic regulation.
This hypothesis originates from reported studies of the tis-
sue RAS regulation. A range of metabolic potent hormones and
conditions closely interact with tissue RAS and it is often hard
to distinguish direct hormonal actions from actions secondary to
tissue RAS stimulation/inhibition. Because of this consistent con-
vergence toward tissue RAS and the well-known potent actions
of especially ANG II, we hypothesize that the effects are mediated
through regulations of tissue RAS. Implications of this hypothesis
may not only change our view on endocrine physiology but
also explain both the origin of some metabolic diseases and the
accompanying complications.
TISSUE RAS REGULATION
Below, we will review the interactions between tissue RAS and
some of the main players in metabolic disease [hyperglycemia,
obesity, hypertension, exercise, GLP-1, cortisol, and vitamin D
(VitD)].
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HYPERGLYCEMIA STIMULATES TISSUE RAS AND VICE VERSA
Patients with diabetes are characterized by an impaired ability to
secrete insulin and/or a decreased sensitivity to insulin. T2D and
metabolic syndrome have consistently been related to an activated
RAS, and several in vitro studies find hyperglycemia to stimulate
tissue RAS in different tissues (9–14). Renin release after GPR91
receptor activation with succinate may partly be the mechanism
of action (15).
A recent 26-weeks randomized controlled trial found that the
ARB valsartan improves both beta cell function and insulin sen-
sitivity in subjects with impaired glucose metabolism (16). The
large NAVIGATOR study found valsartan treatment to relatively
reduce the incidence of diabetes by 14% compared to placebo in
patients with impaired glucose tolerance during 5 years follow up
(8). The DREAM study did not find ACE inhibition with ramipril
for 3 years to significantly reduce the incidence of diabetes but
it did increase regression to normoglycemia (17). Several other
studies in both animals and humans find that ANG II decreases
insulin secretion and sensitivity while these are improved by RAS
inhibitors. Conflicting results do exist, however, with regard to
insulin sensitivity, as recently reviewed (18, 19).
In addition to acutely diminished insulin release, ANG II
decreases beta cell proliferation and stimulates beta cell apoptosis
leading to impaired long-term islet function (20).
OBESITY STIMULATES TISSUE RAS AND VICE VERSA
It is well-known that obesity predisposes to metabolic disease and
that many T2D patients are obese. Several studies in humans
and animals find obesity associated with enhanced activity of
both systemic RAS and adipose tissue RAS (21). Especially, the
AGT synthesis is very developed in adipocytes and contributes
significantly to the systemic pool (22). The activity of tissue RAS
is higher in visceral/central adipose tissue than in subcutaneous
tissue (23), which may explain the risks related to upper body
visceral fat accumulation (24).
Renin–angiotensin system components are complexly involved
in the development of obesity by affections of satiety, energy
expenditure, and adipocyte growth and differentiation (21). ARBs
reduce body weight in both rodents and patients (25, 26). Sur-
prisingly, chronic ANG II infusion also decreases body weight
in rodents (27). However, adipose specific over-activation of
AGT expression increases body weight in mice (28), which may
be the setting that mimics obesity related RAS activation the
best. The apparently contradicting findings probably illustrate the
importance of the local nature of RAS in adipose tissue.
HYPERTENSION STIMULATES TISSUE RAS AND VICE VERSA
It is well-known that ANG II induces hypertension through
vasoconstriction and sodium retention. Hypertension, however,
also activates tissue RAS through mechanical stretch. This has
been shown in vitro and in vivo in several studies in cardiac
myocytes (29) and mesangial cells (30) as well as in skeletal mus-
cle myoblasts (31). Generally, the mechanical stretch is found to
up-regulate tissue RAS synthesis of AGT, ANG II, and AT1Rs.
GLP-1 INHIBITS TISSUE RAS AND VICE VERSA
GLP-1 and ANG II have multiple different actions in a variety of
tissues that are not included in the classical view of either of the
hormones. Interestingly, when the topic is studied in detail, all
GLP-1 actions seem to be counteracted by ANG II. We therefore
question whether the two systems are independent or if GLP-1
actions partly or totally depend on the more widely distributed
tissue RAS. This dependence is supported by several studies.
The circulatory ANG II levels decrease in response to GLP-1
infusion in healthy subjects (32). Exendin-4 (GLP-1R agonist)
attenuated the effect of ANG II-induced hypertension in mice (33)
and in vitro GLP-1 effectively inhibited ANG II-induced mesangial
cell damage (34). GLP-1 and the ARB candesartan additively pre-
vent β-cell apoptosis through the same signaling pathway (20). A
dipeptidyl peptidase-4 inhibitor and valsartan additively improve
both β-cell structure and function in T2D mice (35). Finally, a
recent study provides a novel biochemical pathway on how GLP-1
inhibits ANG II signaling by demonstrating that GLP-1R ago-
nists induce protective actions in glomerular endothelium cells
by inhibiting the post-receptor signaling pathway of ANG II at
phospho-c-Raf(Ser338) via phospho-c-Raf(Ser259) (12). Thus, it
seems likely that GLP-1 from both a functional and biochemical
perspective is an inhibitor of ANG II actions. Since it is difficult
to identify GLP-1 actions that are not counteracted by ANG II,
it is tempting to hypothesize that GLP-1 acts primarily through
down-regulation of tissue RAS.
T2D patients have an impaired incretin effect (36), low lev-
els of GLP-1 (37), and an impaired response to GLP-1 (38). In a
rat model of metabolic syndrome, ARBs were found to increase
fasting plasma levels of GLP-1 by 2.5-fold and increase pancreatic
GLP-1R expression (39). This strongly suggests an AT1R-mediated
decrease in GLP-1 synthesis and GLP-1R expression.
CORTISOL STIMULATES TISSUE RAS AND VICE VERSA
Glucocorticoids are steroid hormones with a wide range of impor-
tant and essential actions. The hormones’ marked impact on
metabolism is revealed in Cushing’s syndrome where excess cor-
tisol induces central obesity, hypertension, osteoporosis, and dia-
betes. These manifestations are similar to those of increased RAS
activity.
Glucocorticoids stimulate AGT transcription and secretion in
adipocytes (40), kidney tubular cells (41, 42), and cardiac fibrob-
lasts (43). In addition, glucocorticoids up-regulate AT1R expres-
sion in vascular smooth muscle cells but do not seem to directly
affect post-receptor signaling (44, 45).
Besides ANG II’s well-known actions on adrenal aldosterone
secretion, it also stimulates cortisol secretion (46, 47).
The above indicates that the metabolic effects of glucocorti-
coids may partly be mediated via up-regulation of tissue RAS. The
anti-inflammatory properties of glucocorticoids, however, cannot
be explained by tissue RAS regulation.
VITAMIN D INHIBITS TISSUE RAS AND (MAYBE) VICE VERSA
Vitamin D has become an important topic in metabolic research
and VitD deficiency has been linked to insulin resistance and
impaired beta cell function (48). The VITAL study found that
VitD receptor activation reduced albuminuria in T2D patients
in a fashion comparable to RAS-inhibition (49). Several human
studies report an inverse relationship between VitD levels and cir-
culating RAS activity (50, 51). In VitD receptor null mice, the renin
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expression and plasma ANG II concentration are increased several-
fold (52). In vitro VitD inhibits pancreatic islet RAS component
synthesis in parallel to the improvement in beta cell secretory
function (53). The VitD induced suppression of renin gene tran-
scription is believed partly to be the mechanism of action (54).
Considerable additional evidence supports the theory of VitD
induced inhibition of RAS at both systemic and tissue level; for
reviews see (54, 55).
In an interesting recent paper, the close interactions between
VitD and the RAS are reviewed from both a functional and evo-
lutionary perspective (56). It is proposed that increased RAS
activity negatively regulates the VitD level through inflammatory
responses and that this explain the pandemic of VitD deficiency
(56). However, the specific mechanisms underlying this effect are
not documented.
REGULAR EXERCISE INHIBITS TISSUE RAS
It is well established that moderate aerobic exercise reduces the
risk of both metabolic and cardiovascular disease in humans (57).
Studies in rodents find chronic exercise to inhibit tissue RAS acti-
vation in the brain (58) (reduced local ACE and AT1R), heart (59,
60) (reduced local ACE and ANG II), and kidney (reduced local
AT1R) (61). These findings suggest that down-regulation of tissue
RAS may partly mediate the beneficial effects related to frequent
exercise.
During exercise, however, tissue RAS seem to be acutely acti-
vated in the kidneys (increased ANG II, ACE, and AGT), which
may function to redistribute blood flow to the muscles (62).
The mechanism behind the different effects of long-term
chronic exercise and short-term acute exercise on tissue RAS activ-
ity is not fully elucidated but may be related to the differences in
sympathetic tone between the two situations. The sympathetic
tone increases acutely during exercise whereas regular exercise has
shown to decrease an elevated sympathetic tone (63). In the kid-
neys, at least, RAS activity increases in response to sympathetic
stimulation.
OTHER HORMONES AND TISSUE RAS
Angiotensin II and vasopressin are both vasoconstrictors and
antidiuretics. In the kidneys, ANG II and vasopressin stimulate
aquaporin-2 insertion in the inner medulla through the AT1R and
V2 receptor, respectively. Interestingly, in AT1R knock-out mice
the vasopressin-induced signaling and aquaporin-2 insertion are
defective (64). This might reflect a dependence of vasopressin on
the tissue RAS.
In the kidney, dopamine functions primarily through the D1
receptor, which is a G-protein coupled receptor similar to the
GLP-1R. Like GLP-1, and in contrast to ANG II, dopamine inhibits
tubular salt reabsorption and seems to prevent kidney damage
(65). Interestingly, dopamine is found to inhibit AGT synthesis
in proximal tubule cells (65), suppress renin expression (66), and
down-regulate AT1Rs (67, 68).
HYPOTHESIS
TISSUE RAS IS CENTRAL TO CELL REGULATION, AND THE EFFECT OF
MULTIPLE HORMONES DEPEND ON THE SYSTEM
Multiple hormones and conditions interact closely with the widely
distributed tissue RAS. The local effects of ANG II show great
diversity in different tissues and often mimic or oppose the actions
of the hormones, which regulate tissue RAS.
We therefore hypothesize that the apparent actions of many
hormones are induced through alterations in tissue RAS activity.
Thus, it is the cellular pathways of tissue RAS that in the end effect
actions. The dependence can be direct and strong (e.g., GLP-1)
or partial and less direct (e.g., VitD) mediated via regulations of
genes coding for RAS components.
Especially hormones acting through G-Protein coupled recep-
tors seem to be likely candidates for direct tissue RAS dependent
hormones. The nature of the receptor (RAS stimulating or inhibit-
ing) along with the distribution will determine the effects of the
hormone.
INCREASED TISSUE RAS ACTIVITY IS RESPONSIBLE FOR METABOLIC
DISEASE
The observation of a relationship between RAS and metabolic
disease is not new (6, 69). An activated RAS promotes all the
characteristic properties of metabolic syndrome [hypertension,
hyperglycemia, insulin resistance, obesity, and dyslipidemia (6)].
The novelty lies in the explicit coupling between tissue RAS and the
major risk factors of metabolic disease. If tissue RAS completely or
partly underlies the actions of GLP-1,VitD, and cortisol as hypoth-
esized, then the metabolic power of the system is greater than first
anticipated. Therefore, we propose that an activated tissue RAS is
mandatory in the pathogenesis of most metabolic diseases, includ-
ing T2D. The different degrees of tissue RAS activation in different
tissues will determine the phenotype of the disease.
The activity of RAS also rises physiologically during pregnancy,
which could partly explain the origin of gestational diabetes in pre-
disposed individuals (70). In addition, preeclampsia is potentially
the result of extreme RAS activation (70).
METABOLIC DISEASE INITIATES DUE TO THE SELF-REINFORCING
PROPERTIES OF TISSUE RAS
As argued above and illustrated in Figure 1, tissue RAS is regu-
lated by well-known risk factors of diabetes and through several
positive feedback mechanisms. ANG II even seems to stimulate its
own secretion (71). This makes the basis for an unstable system
and we hypothesize that T2D and other metabolic diseases develop
when tissue RAS becomes self-reinforcing. This may happen due
to one far-off parameter (hyperglycemia in type 1 diabetes (T1D)
or high dose glucocorticoid treatment) but is often caused by a
sum of risk factors, like the combination: obesity, inactivity, high
glycemic index diet, and VitD deficiency.
METABOLIC COMPLICATIONS ARE CAUSED BY INCREASED TISSUE
RAS ACTIVITY
The multiple different effects of ANG II depend on which tis-
sue/cell is involved, the receptor, and the time frame of stimulation.
Many of ANG II’s immediate effects (e.g., vasoconstriction) are
mediated via the AT1R through classical G-protein-dependent
signaling pathways (72).
Stimulation of the AT1R also activates the membrane-bound
NAD(P)H oxidase leading to increased generation of reactive
oxygen species (ROS). The NAD(P)H formed ROS may activate
mitochondrial KATP channels to additionally burst mitochondr-
ial ROS generation (73). Alternatively, the mitochondrial ROS
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FIGURE 1 |Tissue RAS activity is controlled by several well-known
metabolic hormones and conditions. This control often involves positive
feedback mechanisms, which makes the basis for an unstable system and
progression of disease. We hypothesize that metabolic complications arise
as a consequence of pathological activated tissue RAS.
formation may be mediated via local mitochondrial ANG II sen-
sitive receptors (74). After its generation, intracellular ROS can
activate many down-stream molecules such as mitogen-activated
protein kinases, protein tyrosine phosphatases, protein tyrosine
kinases, and transcriptional factors, which if chronically acti-
vated will promote inflammation, atherosclerosis, thrombosis, and
fibrogenesis (72, 73).
In almost all organ systems, RAS activation has been asso-
ciated with degeneration, tissue remodeling, and dysfunction
that are likely secondary to ROS formation and phenotypic
known as the metabolic syndrome. Practically all complications
in diabetes are related to the RAS and increased ANG II levels
including ischemia, myocardial infarction, stroke, nephropathy,
cardiomyopathy, retinopathy (75), polyneuropathy (76), and
erectile dysfunction (77).
We therefore hypothesize that the majority of complications
seen in metabolic disease are consequences of a pathological-
activated tissue RAS. Thus, hyperglycemia may not directly induce
complications apart from the ability to stimulate tissue RAS.
Although this statement may sound controversial, we do not find
it to conflict with the leading theory on the pathogenesis of dia-
betic complications, The Brownlee hypothesis (78). The Brownlee
hypothesis states that all pathological metabolic pathways induced
by hyperglycemia are secondary to increased ROS (78). We just add
an extra link to the chain so that hyperglycemia stimulates ROS
production via stimulation of tissue RAS. By introducing ROS for-
mation secondary to tissue RAS activation as a unifying mediator
of complications, we have plausibly linked all the major risk factors
in metabolic disease.
Essentially, the full theory simplifies T2D to a complication of
a malfunctioning tissue RAS which places it next to other compli-
cations. However, the “T2D complication” may be special in the
ability to accelerate RAS over-activity (hyperglycemia induced)
and thereby other complications. According to the hypothesis, tis-
sue RAS must be pathologically activated prior to the onset of
T2D and this may explain why complications often exist at the
time of T2D diagnosis. By contrast, the complications seen in
T1D will only occur if glucose level is uncontrolled and allowed to
secondarily activate tissue RAS.
Both T1D and T2D are associated with a markedly increased
risk of bone fractures despite increased bone mineral density in
obese T2D patients (79,80). Tissue RAS is also present in bones and
involved in bone remodeling (81). In an eight-week interventional
study, ARBs improved bone mass and strength in osteoporotic rat
femurs (82). Consistent with this, an observational study demon-
strated that ARB treatment significantly reduced fracture risk
(hazard ratio 0.76) in older adults (83). We therefore hypothesize
that the osteoporotic complication is caused primarily by an acti-
vated bone tissue RAS and that the positive VitD effects on bone
metabolism are partly due to RAS-inhibition. Equally, the well-
known pro-osteoporotic properties of cortisol as well as the less-
known anti-osteoporotic properties of GLP-1 (84, 85) are caused
by bone tissue RAS stimulation and inhibition respectively.
DISCUSSION
Tissue RAS is regulated by multiple factors of which we have only
mentioned some. We have focused on the interaction between tis-
sue RAS and the major metabolic hormones and conditions, but
this is certainly not the complete story. Tissue RAS is present in
almost every tissue and exert multiple different actions determined
by the involved cells. Thus, we speculate that tissue RAS should be
seen as a common effectuating machinery required for multiple
different purposes.
From an evolutionary point of view, it is cost-effective to have
a common system to potentiate and effect the actions of the regu-
lating hormones. Interestingly, the RAS is also found in primitive
animals without a closed circulatory system (86), which indicate
that the system is far more than a mediator of vasoconstriction.
The RAS offers multiple targets for regulation as we have seen
(AGT, renin,AT1R,ACE, down-stream signaling) and several more
which we have excluded (prorenin receptor, ACE2, AT2R, AT4R,
neutral endopeptidase, chymase, Mas receptor). We have focused
on the ANG II–AT1R interactions since these are the best described
and considered the most important. However, the system is com-
plex and several other components probably play significant roles
as well. Especially, the AT2Rs have come in focus in recent years
and seem to be important counter-regulators of AT1R function
(87). This may be of particular importance when the AT1Rs are
pharmacologically blocked.
While we have focused only on a few regulators of tissue RAS the
same is true regarding the implications of the hypothesis. We will
likely identify that many known disorders are caused by a malfunc-
tioning tissue RAS in specific organs and these could likely include
inflammatory bowel disease, psoriasis, preeclampsia, Alzheimer’s
disease, and depression.
It is essential to emphasize the importance of the local nature of
tissue RAS and it is somewhat misleading to talk about a general
over-activity. Even the circulating classical RAS should to some
degree be considered a local independent system when compared
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to the tissue level systems. However, since tissue RAS in different
tissues have many regulatory hormones and conditions in com-
mon, it makes sense to talk about a general direction of activity
level. Additionally, although paracrine acting, there seem to be
a degree of “spill over” of RAS components from one tissue to
another. This is of course very pronounced with the classical cir-
culating RAS but adipocyte AGT synthesis, as an example, also
contributes significantly to the total AGT pool.
The local environments with respect to angiotensin concen-
trations and angiotensin sensitivity are generally hard to assess,
especially in humans. In addition, evidence suggests that besides
paracrine and autocrine actions, ANG II exerts intracrine effects
mediated by intracellular located receptors. ANG II may be inter-
nalized or act immediately after intracellular synthesis without
ever leaving the cell (2, 88). This may partly explain why the
importance of tissue RAS is still broadly unacknowledged and why
classical extracellular RAS inhibitors in many ways are insufficient.
If the phenotypes of metabolic diseases and the complications
seen in relation hereto are caused by locally activated tissue RAS as
hypothesized, diagnosing and treating an activated RAS become
the primary target in the clinic. Screening for activated tissue RAS
in relevant tissues instead of elevated glycemic level would the-
oretically serve as an early and more efficient marker of the risk
of complications – including T2D. The urinary excretion of AGT
has been proposed as a non-invasive marker of renal tissue RAS
activity (89). Although this particular method may be imperfect
(90), the concept of assessing specific tissue RAS activity may be
of great diagnostic value in the future.
Provided that the proposed hypothesis is correct, it should the-
oretically be possible to prevent T2D by securing that tissue RAS
never reaches a high or self-reinforcing level, which emphasizes the
importance of prophylaxis and early intervention. Besides lifestyle
interventions, drugs aiming to decrease tissue RAS should be pre-
ferred and drugs targeting the intracellular part of tissue RAS or
some of the newer extracellular components may be the drugs of
tomorrow.
A few studies suggest that the ANG II-induced ROS formation
is mediated through AT1Rs located directly on the mitochondrial
membranes (74), whereas one study cannot confirm this relation-
ship (91). If indeed existing and functional, these mitochondrial
AT1Rs seem particular attractive to block selectively to prevent
complications.
The hypothesis obviously needs further investigation. While
several interactions with tissue RAS are well described, their indi-
vidual importance is less characterized. In fact, the importance
of tissue RAS, in general, is poorly understood and according to
this hypothesis greatly underestimated. The local nature of the
systems, however, makes the design of appropriate experiments
harder. Interesting pathways can be elucidated in vitro but the
importance in vivo can be difficult to extrapolate. One possible
experimental approach is the use of AT1R knock-out mice. Accord-
ing to the hypothesis, these mice would have defective responses
to hormones, which primarily depend on tissue RAS.
In conclusion, we have hypothesized that the tissue RAS is in
the very center of metabolic regulation and is the true effector
of multiple hormones. Implications of this hypothesis suggest
a new unifying understanding of the nature, initiation, and
complications of metabolic disease.
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